1 2 3 4 5 6 7 8 9
читать далее ... berg R , DeWood M DeMana A et al for The Milnnone-Dobutamine Study Group Comparative efficacy of short-term intravenous infusions of milnnone and dobutamme in acute congestive heart failure following acute myocardial mfarction Clin Cardiol 1996, 19, 21-30 11 Krell M Kline E , Bates E et al Intermittent, ambulatory dobutamme infusions in patients with severe congestive heart failure Am Heart J 1986,112, 787-791 12 0 Connor С, Gattis W, Uretsky В et al for the FIRST Investigators Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure Insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 1999, 138 78-86 13 Jaski В Fifer M Wnght R et al Positive inotropic and vasodilator actions of milnnone in patients with severe congestive heart failure J Chn Invest, 1984, 75, 643-649 14 Leier С General overview and update of positive motiopic therapy Am J Med , 1986, 81 (4C) 40-45 15 Janicki J , Shroff S , Weber К Physiologic response to the inotropic and vasodilator properties of enoximone Am J Cardiol, 1987, 60 (5), 15C-20C 16 Tsvetkova Т , Farber D Abraham W et al Comparative hemodynamic effects of milnnone and dobutamme in heart failure patients treated chronically with carvedilol (abstr 135) J Card Fail, 1998. 4 (3, suppi 1), 36 17 Gilbert E , Bnstow M , Mason J The acute hemodynamic response to low dose enoximone (MDL 17,043) An oral dose-range study Am J Cardiol, 1987, 82, 57C-62C 18 Dibianco R, Shabetai R , Kostuk W et al for the Milnnone Study Group A comparison of oral nulnnone, digoxin, and their combination m the treatment of patients with chronic heart failure N Engi J Med , 1989, 320 677-683 19 Lowes В Higginbotham M , Petrovich L et al Low dose enoximone improves exercise capacity in chronic heart failure Enoximone Study Group J Am Coil Cardiol, 2000, 36 (2), 501-508 20 Follath F , Hinkka S , Jager D et al Dose-ranging and safety with intravenous levosimendan m low-output heart failure experience in 3 pilot studies and outline of the LIDO tnal Am J Cardiol , 1999, 83 (Suppi I) (I)21-(I)25 21 Moiseyev V, Andrejev N , Lehtonen L et al Randomized study on safety and efficacy of levosimendan in patients with left ventncular failure after an acute myocardial infarction J Cardiac Failure 1999 5 (suppi I) 42 22 Kersten J , Montgomery M Pagel P Warltier D Levosimendan, a new positive inotropic drug, decreases myocardial mtarct size via activation of K(ATP) channels Anesth Analg , 2000, 90, 5-11 23 Gruhn N , Nielsen-Kudsk J , Theilgaard S et al Coronary vasorelaxant effect of levosimendan, a new modilator with calcium-sensitizing properties J Cardiovasc Pharmacol 1998, 31, 741-749 24 Page! P Haikala H Pentikainen P et al Pharmacology of levosimendan a new myofilament calcium sensitizer Cardiovasc Drug Rev 1996 14 286-316 25 Varro A , Papp J Classification of positive inotropic actions based on electrophyslologic characteristics where should calcium sensitizers be pИсточник: Павликова Е.П. и др. Клиническая фармакология и терапия. 2005. №3. С.79-84